Compass Pathways Q3 net loss narrows on lower R&D charges

Overview

• UK biotech's Q3 operating income missed analyst expectations

• Net loss narrowed significantly from prior year, mainly due to warrant fair value adjustments

• Company ended Q3 with $444 mln cash, sufficient to fund operations into 2028

Outlook

• Company expects to launch COMP360 in H1 2027, pending FDA approval

• COMP360 may receive accelerated FDA review, potentially shortening approval to 1-2 months

• Company expects current cash to fund operations and capital expenditures into 2028

Result Drivers

• LOWER R&D COSTS - Co said reduced clinical trial and discovery program expenses drove lower research and development costs

• COMMERCIAL PREPARATION - Co attributed higher selling, general and administrative expenses to investments in launch readiness for COMP360

• WARRANT FAIR VALUE - Co said narrowing net loss was mainly due to non-cash fair value adjustments related to warrants

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Compass Pathways PLC is $20.00, about 137.8% above its November 2 closing price of $8.41

Reuters Recommended Reads

• Nov 2 - Recursion Pharmaceuticals Q3 net loss narrows more than expected on lower costs

• Nov 2 - Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)